CENTURY LITHIUM CORP.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
(Unaudited - Expressed in Canadian Dollars)

FOR THE THREE MONTHS ENDED MARCH 31, 2026

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a) continuous disclosure requirement, if any auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these Condensed Consolidated Interim Financial Statements.

CENTURY LITHIUM CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
(Unaudited - Expressed in Canadian Dollars)
AS AT MARCH 31, 2026

	March 31, 2026	December 31, 2025
ASSETS		
Current		
Cash and cash equivalents	$10,504,389	$ 5,200,725
Marketable securities	63,000	51,000
Receivables and prepaid expenses (Note 3)	111,957	96,923
	10,679,346	5,348,648
Reclamation bonds	28,976	28,976
Plant and equipment (Note 5)	1,263,358	1,207,866
Intangible asset	1,095,150	1,102,600
Exploration and evaluation assets (Note 6)	48,661,130	48,022,515
	$61,727,960	$55,710,605
LIABILITIES AND EQUITY		
Current		
Accounts payable and accrued liabilities	$213,914	$184,900
	213,914	184,900
Equity		
Capital stock (Note 7)	98,068,169	93,582,272
Reserves (Note 8)	15,261,045	13,360,055
Deficit	(51,815,168)	(51,416,622)
	61,514,046	55,525,705
	$61,727,960	$55,710,605

Approved and authorized by the Board on May 22, 2026

"Bryan Disher"	Director	*"Don Myers"*	Director
Bryan Disher		Don Myers	

The accompanying notes are an integral part of these consolidated interim financial statements

CENTURY LITHIUM CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(Unaudited - Expressed in Canadian Dollars
THREE MONTHS ENDED MARCH 31

	2026	2025
GENERAL AND ADMINISTRATIVE EXPENSES		
Administrative, office and miscellaneous	$95,202	$73,971
Consulting fees	27,361	9,137
Directors' fees	48,917	68,000
Finance costs (Note 4)	-	10,083
Legal	37,598	27,613
Salaries and wages (Note 9)	73,198	113,999
Share-based compensation	54,731	104,241
Shareholder communications	45,697	68,840
Transfer agent and filing fees	12,792	14,372
Travel	6,500	5,639
	(401,996)	(495,895)
Foreign exchange loss	(32,761)	(16,674)
Interest income	24,211	31,188
Unrealized gain on marketable securities	12,000	15,000
Loss and comprehensive loss for the period	$(398,546)	$(466,381)
Basic and diluted earnings per common share	$(0.00)	$(0.00)
Weighted average number of common shares outstanding – basic and diluted	168,035,689	149,499,548

The accompanying notes are an integral part of these consolidated interim financial statements.

CENTURY LITHIUM CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
(Unaudited - Expressed in Canadian Dollars)
FOR THE THREE MONTHS ENDED MARCH 31

	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Loss for the period	$(398,546)	$(466,381)
Items not affecting cash:		
Finance costs	-	10,083
Share-based compensation	54,731	104,241
Unrealized (gain) on marketable securities	(12,000)	(15,000)
Foreign exchange loss	32,761	16,674
Changes in non-cash working capital items:		
Change in receivables and prepaid expenses	(15,034)	153,256
Change in accounts payable and accrued liabilities	24,139	74,908
Net cash flows used in operating activities	(313,949)	(122,219)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of equipment	(55,492)	(168,219)
Expenditures on exploration and evaluation assets	(626,293)	(964,760)
Net cash flows used in investing activities	(681,785)	(1,132,979)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from unit offering (Note 7)	7,000,000	-
Share issuance costs	(810,943)	-
Proceeds from exercise of warrants	143,100	-
Lease payments	-	(86,547)
Net cash flows used in financing activities	6,332,156	(86,547)
Effect of foreign exchange on cash	(32,758)	(16,674)
Change in cash and cash equivalents during the period	5,303,664	(1,358,419)
Cash and cash equivalents, beginning of period	5,200,725	5,982,883
Cash and cash equivalents, end of period	$10,504,389	$4,624,465

Supplemental disclosures with respect to cash flows (Note 10)

The accompanying notes are an integral part of these consolidated interim financial statements.

CENTURY LITHIUM CORP.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY
(Unaudited - Expressed in Canadian Dollars)
FOR THE THREE MONTHS ENDED MARCH 31

	Capital Stock				
	Number	**Amount**	**Reserves**	**Deficit**	**Total**
Balance, as at December 31, 2025	165,285,381	$93,582,272	$13,360,055	$(51,416,622)	$55,525,705
Share issuance costs – cash	-	(810,943)	-	-	(810,943)
Share issuance costs – broker warrants	-	(75,251)	75,251	-	-
Shares issued – LIFE offering	14,893,616	5,212,766	1,787,234	-	7,000,000
Shares issued for exercise of warrants	349,500	159,326	(16,226)	-	143,100
Share-based compensation	-	-	54,731	-	54,731
Loss for the period	-	-	-	(398,546)	(398,546)
Balance as at March 31, 2026	180,528,497	$98,068,169	$15,261,045	$(51,815,168)	$61,514,046
Balance, as at December 31, 2024	149,499,548	$89,607,276	$12,598,690	$(49,428,989)	$52,776,977
Share-based compensation	-	-	104,241	-	104,241
Loss for the period	-	-	-	(466,381)	(466,381)
Balance as at March 31, 2025	149,499,548	$89,607,276	$12,702,931	$(49,895,370)	$52,414,837

The accompanying notes are an integral part of these consolidated interim financial statements.

1. NATURE OF OPERATIONS AND LIQUIDITY

Century Lithium Corp. was incorporated pursuant to the Business Corporations Act (Saskatchewan) on August 23, 1991. It is a publicly traded company listed on the TSX Venture Exchange under the symbol “LCE” and on the OTCQX market in the United States under the symbol “CYDVF”, and on the Frankfurt Stock Exchange under the symbol "C1Z". Century is an exploration and development-stage company engaged in the identification, acquisition, exploration, and development of lithium and other mineral properties in the United States. The Company’s primary focus is the advancement and potential development of its Angel Island Lithium Project (“Angel Island”) in Esmeralda County, Nevada, USA.

The head office and records of the Company are located at Suite #1030 – 505 Burrard Street, Vancouver, BC V7Y 1G4.

On February 23, 2026, the Company released the results of its Updated Feasibility Study (the “2026 Feasibility Study”) on Angel Island, which established Mineral Reserves and supports the technical and economic viability of Angel Island. The recoverability of the amounts shown for exploration and evaluation assets is dependent upon the Company's ability to obtain the necessary financing to bring Angel Island into commercial production. The Company does not generate cash flows from operations and therefore relies principally on the issuance of securities for financing. The Company will require additional financing to advance Angel Island to construction; however, this is not expected to occur within the next twelve months.

These condensed interim consolidated financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business. Although the Company has incurred losses from inception, the Company has working capital of $10,465,432 as at March 31, 2026 (December 31, 2025: $5,163,748).

2. BASIS OF PREPARATION

Statement of Compliance with International Financial Reporting Standards

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34, *Interim Financial Reporting*, as issued by the International Accounting Standards Board ("IASB"). They do not include all the information required for a complete set of annual financial statements and should be read in conjunction with the Company's audited annual consolidated financial statements for the year ended December 31, 2025, which were prepared in accordance with IFRS Accounting Standards as issued by the IASB ("IFRS"). Selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the most recent annual financial statements.

2. BASIS OF PREPARATION (cont'd…)

Basis of consolidation

These condensed consolidated interim financial statements include the accounts of the Company and its wholly owned subsidiaries, Cypress Holdings (Nevada), Ltd. and 2845028 Ontario Inc. All intercompany balances and transactions have been eliminated on consolidation.

Functional Currency

These condensed consolidated interim financial statements are presented in Canadian dollars, which is also the functional currency of the parent company. The functional currency of Cypress Holdings (Nevada), Ltd. is the Canadian dollar.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date. Differences arising on settlement or translation of monetary items are recognized in profit or loss. Non-monetary items measured at historical cost in a foreign currency are translated using the exchange rate at the date of the initial transaction.

Accounting policies, estimates and judgements

The accounting policies, methods of computation and significant estimates and judgments applied in these condensed consolidated interim financial statements are consistent with those applied in the Company's audited annual consolidated financial statements for the year ended December 31, 2025, except for the adoption of the amendments described below.

Effective January 1, 2026, the Company adopted the amendments to IFRS 9 — Financial Instruments and IFRS 7 — Financial Instruments: Disclosures, "Amendments to the Classification and Measurement of Financial Instruments" (the "Amendments"), issued by the IASB. The Amendments clarify, among other matters, the requirements for derecognition of financial liabilities settled through electronic payment systems and introduce an accounting policy election permitting derecognition before the settlement date when specified conditions are met.

The Company has elected to derecognize financial liabilities settled through wire transfers, automated clearing house (ACH) transactions, and bank-initiated electronic bill payments before the settlement date. The Company made this election because, for each of these payment systems, it has no practical ability to withdraw, stop, or cancel payment instructions once initiated, no practical ability to access the cash for settlement, and the settlement risk associated with the payment system is insignificant. The election applies to all electronic payment systems used by the Company.

Cheques are not subject to this election. Accordingly, the Company has revised its accounting policy to derecognize financial liabilities settled by cheque upon clearance by the bank, rather than upon issuance. The Amendments have been applied retrospectively; the Company assessed the impact at December 31, 2025 and March 31, 2026, and concluded that the impact was not material to the consolidated financial statements at either date. As a result, no adjustment has been recorded to the comparative consolidated statement of financial position.

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Approval of financial statements

The Board of Directors approved these interim financial statements for issue on May 22, 2026.

3. RECEIVABLES AND PREPAID EXPENSES

Receivables and prepaids are comprised of:

	March 31, 2026	December 31, 2025
GST receivable	$29,507	$12,291
Prepayments	82,450	84,632
Total	$111,957	$96,923

4. LEASES

The Company previously held a lease for a refining facility located in the Amargosa Valley of Nye County, Nevada, used to operate the lithium extraction Demonstration Plant. The lease had an initial term of forty-eight months running from December 1, 2021 to November 30, 2025, at a cost of US$22,500 per month.

The lease was not renewed upon expiry. As at December 31, 2025, both the right-of-use asset and the associated lease liability were fully derecognized. As a result, no depreciation of the right-of-use asset, lease finance costs or lease payments are recorded for the three months ended March 31, 2026 (March 31, 2025 — depreciation of $64,581 capitalized to exploration and evaluation assets, finance costs of $10,083 recognized in profit or loss, and lease payments of $86,547).

During the three months ended March 31, 2026, the Company incurred $nil (March 31, 2025 — $nil) on short-term and low-value leases that were not reflected as right-of-use assets and lease liabilities.

5. PLANT AND EQUIPMENT

	Demonstration Plant	Equipment	Total
Cost			
Balance, December 31, 2025	$ 7,192,835	11,199	7,204,034
Additions for the period	50,810	4,682	55,492
Balance, March 31, 2026	$ 7,243,645	15,881	$7,259,526
Accumulated depreciation			
Balance, December 31, 2025	5,991,509	4,659	5,996,168
Depreciation for the period	-	-	-
Balance, March 31, 2026	5,991,509	4,659	5,996,168
Net book value			
Balance, December 31, 2025	$1,201,326	$6,540	$1,207,866
Balance, March 31, 2026	$1,252,136	$11,222	$1,263,358

5. PLANT AND EQUIPMENT (cont'd…)

The Company's Demonstration Plant was previously located at a leased facility in the Amargosa Valley of Nevada. The lease expired on November 30, 2025 and was not renewed. The Demonstration Plant was dismantled and relocated to the Company's site in Tonopah, Nevada where it is being reassembled and recommissioned. During this period, the Demonstration Plant is not available for use and depreciation is not charged. Depreciation will resume when the asset is recommissioned and charged over the asset's revised remaining useful life, accounted for prospectively as a change in accounting estimate.

During the three months ended March 31, 2026, no depreciation was recognized in the period (March 31, 2025 — depreciation of $688,257 was recorded and capitalized to exploration and evaluation assets).

6. EXPLORATION AND EVALUATION ASSETS

March 31, 2026 *(3 Months)*	Angel Island	Goat Claims	Total
Acquisition Costs:			
Balance as at December 31, 2025	$7,039,565	$75,950	$7,115,515
Balance, March 31, 2026	7,039,565	75,950	7,115,515
Exploration and evaluation costs:			
Incurred during the period:			
Administrative expenses	7,343	-	7,343
Assaying/sampling	241	-	241
Consulting	177,245	-	177,245
Feasibility	178,330	-	178,330
Demonstration plant operating expenses	79,755	-	79,755
Travel	13,073	-	13,073
Wages	182,628	-	182,628
	638,615	-	638,615
Balance, beginning of year	40,907,000	-	40,907,000
Balance, end of period	41,545,615	-	41,545,615
Total, March 31, 2026	$48,585,180	$75,950	$48,661,130

6. EXPLORATION AND EVALUATION ASSETS (cont'd…)

December 31, 2025 *(12 months)*	Angel Island	Goat Claims	Total
Acquisition costs:			
Balance, beginning of year	7,039,565	$ 75,950	$ 7,115,515
Exploration and evaluation costs:			
Incurred during the period:			
Administrative expenses	261,169	-	261,169
Assaying/sampling	11,911	-	11,911
Consulting	870,485	-	870,485
Feasibility	278,185	-	278,185
Other/supplies	5,719	-	5,719
Demonstration plant operating expenses	3,498,532	-	3,498,532
Transportation/fuel	1,130	-	1,130
Travel	86,712	-	86,712
Wages	724,681	-	724,681
	5,738,524	-	5,738,524
Balance, December 31, 2024	35,168,476	-	35,168,476
Balance, December 31, 2025	40,907,000	-	40,907,000
Total Balance December 31, 2025	$47,946,565	$75,950	48,022,515

Claims

The contiguous Dean, Glory, Enertopia and Goat Claims properties collectively comprise the Company's Angel Island Project in Esmeralda County, Nevada, USA. The Company also holds a 49% interest in the Gunman Project (White Pine County, Nevada) and a Water Rights Permit in Clayton Valley, Nevada. There were no acquisitions, dispositions, or changes to the underlying claim agreements during the three months ended March 31, 2026.

Impairment

Management assessed whether any indicators of impairment existed at March 31, 2026 in respect of the Company's exploration and evaluation assets, in accordance with IFRS 6. Based on the results of the 2026 Feasibility Study, the Company's continued advancement of permitting activities, and the Company's ability and intent to fund ongoing exploration and evaluation expenditures, management identified no indicators of impairment as at March 31, 2026.

7. CAPITAL STOCK

Authorized
An unlimited number of common shares without par value.

Issuances during the period ended March 31, 2026:

Listed Issuer Financing Exemption ("LIFE") Offering (the "2026 Offering")

On March 16, 2026, the Company completed the 2026 Offering, a brokered offering pursuant to the listed issuer financing exemption. The Company issued 14,893,616 units ("Units") at a price of $0.47 per Unit for gross proceeds of $7,000,000. Each Unit consisted of one common share and one common share purchase warrant ("Investor Warrant"). Each Investor Warrant entitles the holder to acquire one common share at an exercise price of $0.65 per share for a period of 60 months from the closing date.

The gross proceeds were allocated between share capital ($5,212,766) and warrant reserve ($1,787,234) using the residual value method, with share capital measured by reference to the closing market price of the Company's common shares on the closing date and the warrant reserve representing the residual amount.

In connection with the 2026 Offering, the Company paid share issuance costs in cash totaling $810,943 and issued 446,808 broker warrants (the "Broker Warrants") to the agent as additional compensation. Each Broker Warrant entitles the holder to acquire one common share at an exercise price of $0.65 per share for a period of 60 months, expiring March 16, 2031. The fair value of the Broker Warrants of $75,251 was recorded in reserves as a share-issuance cost (see Note 8).

Exercise of share purchase warrants

During the three months ended March 31, 2026, the Company also issued 349,500 common shares on the exercise of share purchase warrants for gross proceeds of $143,100. The original $16,226 fair value of these warrants was transferred from reserves to capital stock.

Issuances during the three months ended March 31, 2025:

The Company had no share issuances during the three months ended March 31, 2025.

7. CAPITAL STOCK (Cont'd…)

Issuances during the year ended December 31, 2025:

Listed Issuer Financing Exemption ("LIFE") Offering (the "2025 Offering")

During the year ended December 31, 2025, the Company completed the 2025 Offering, which was closed in two tranches as follows:

Closing date	Units issued	Gross proceeds	Warrant expiry
August 1, 2025	9,559,833	$2,867,950	August 1, 2030
August 29, 2025	6,226,000	$1,867,800	August 29, 2030
Total	**15,785,833**	**$4,735,750**	

Each unit consisted of one common share and one common share purchase warrant exercisable at $0.45 per share for 60 months ("Investor Warrant").

The gross proceeds of $4,735,750 were allocated between share capital ($4,357,773) and warrant reserve ($377,977) using the residual value method.

In connection with the Offering, the Company paid cash commissions of $284,999 and issued 841,855 warrants to arm's-length finders ("Finder's Warrant"). Each Finder's Warrant entitles the holder to purchase one common share at $0.30 per share for 36 months. The fair value of the Finder's Warrants of $97,778 was recorded in reserves as a share-issuance cost.

8. RESERVES

Reserves comprise amounts recognized in respect of share-based compensation arrangements (including stock options and DSUs), and share purchase warrants (including broker warrants).

The Company has a Long-Term Incentive Plan ("LTIP") under which it is authorized to grant options, restricted share units and deferred share units ("DSUs") to Directors, Officers, employees, and consultants, to acquire up to 10% of the issued and outstanding common stock of the Company. The exercise price of each option is set by the Directors but cannot be less than the closing price on the grant date. The options can be granted for a maximum term of 10 years and vest at the discretion of the Board of Directors.

Stock options

Stock option transactions are summarized as follows:

	Number of Options	Weighted Average Exercise Price
Outstanding at December 31, 2025 and March 31, 2026	7,827,167	$1.22

8. RESERVES (Cont'd…)

The following stock options were outstanding at March 31, 2026:

	Number of Shares	Exercise Price	Expiry Date
Stock options:			
	750,000	$ 1.250	May 3, 2026
	1,670,000	$ 2.260	November 22, 2026
	750,000	$ 1.840	April 4, 2027
	645,000	$1.060	November 17, 2027
	1,318,000	$ 1.030	April 24, 2028
	450,000	$ 0.940	June 29, 2028
	845,000	$ 0.590	November 29, 2028
	845,000	$ 0.320	December 11, 2029
	254,167	$ 0.450	September 16, 2030
	300,000	$ 0.300	October 17, 2030
	7,827,167	**$ 1.217**	

No stock options were granted during the three months ended March 31, 2026 (March 31, 2025 — nil). Share-based compensation related to stock options of $35,930 was recognized during the three months ended March 31, 2026 (March 31, 2025 — $104,241).

Deferred share units

On September 16, 2025, the Company granted 254,167 DSUs to independent directors with a grant-date fair value of $0.30 per DSU. The DSUs vest in full on September 16, 2026 and are settled in common shares of the Company when a director leaves the Company, with no cash alternative. The DSUs are accounted for as equity-settled share-based payment arrangements in accordance with IFRS 2.

As at March 31, 2026, 254,167 DSUs were outstanding (December 31, 2025 — 254,167), of which none had vested. Share-based compensation related to DSUs of $18,801 was recognized during the three months ended March 31, 2026 (March 31, 2025 — nil).

Warrants

On March 16, 2026, the Company issued 14,893,616 Investor Warrants and 446,808 Broker Warrants in connection with the 2026 Offering (Note 7).

Investor Warrants

Each Investor Warrant entitles the holder to purchase one common share of the Company at an exercise price of $0.65 per share for a period of 60 months from the grant date, expiring March 16, 2031.

In accordance with the Company's accounting policy, the residual value method was applied to allocate gross proceeds of the 2026 Offering between share capital ($5,212,766) and warrant reserve ($1,787,234). Under this method, the fair value of the common shares issued was measured using the closing market price of the Company's shares on the grant date of $0.35. The residual portion of the proceeds, after deducting the fair value allocated to common shares, was recorded as warrant reserve.

8. RESERVES (Cont'd…)

Broker Warrants

The Company issued 446,808 Broker Warrants to the agent as additional compensation. Each Broker Warrant entitles the holder to acquire one common share at an exercise price of $0.65 per share for a period of 60 months, expiring March 16, 2031.

The fair value of the Broker Warrants of $75,251 was estimated at the grant date using the Black-Scholes option pricing model. Key assumptions were a market price of $0.35, an exercise price of $0.65, an expected life of five years, expected volatility of 72.48%, a risk-free interest rate of 2.96%, and a dividend yield of nil. The weighted-average fair value was $0.17 per warrant. The fair value of the Broker Warrants was recorded in reserves as a share-issuance cost.

Warrant Exercises

During the three months ended March 31, 2026, the Company issued 349,500 common shares on the exercise of share purchase warrants for gross proceeds of $143,100. The original $16,226 fair value of the exercised warrants was transferred from reserves to capital stock.

Share purchase warrant transactions are summarized as follows:

	Number of Warrants	Weighted Average Exercise Price
Outstanding at December 31, 2025	16,627,688	$0.44
Issued — 2026 Offering (Note 7)	15,340,424	$0.65
Exercised	(349,500)	$0.41
Outstanding at March 31, 2026	**31,618,612**	**$0.54**

The following share purchase warrants were outstanding at March 31, 2026:

Number of Warrants	Exercise Price	Expiry Date
9,304,833	$0.45	August 1, 2030
6,226,000	$0.45	August 29, 2030
376,355	$0.30	August 1, 2028
371,000	$0.30	August 29, 2028
15,340,424	$0.65	March 16, 2031
31,618,612	**$0.54**	

9. RELATED PARTY TRANSACTIONS

Key management compensation

Key management personnel consist of the Company's Directors and Officers. The aggregate amount paid or accrued to key management personnel, or companies under their control, was as follows:

	March 31, 2026	March 31, 2025
Directors' fees	48,917	68,000
Salaries and wages	12,500	50,000
General and administrative expenses	80,374	51,596
Capitalized to exploration and evaluation assets	122,587	100,822
Share-based compensation	25,311	41,280
Total	$ 289,690	$ 311,699

As at March 31, 2026, $Nil (December 31, 2025 - $17,496) is included in accounts payable and accrued liabilities owing to Directors and/or companies under their control.

Administrative services agreement

The Company operates from premises of a private company partly owned by a director of the Company. The Company receives office and administrative services under this arrangement for $12,000 per month, cancellable on three months' notice by either party.

Bookkeeping and accounting services agreement

The Company engages Tompkins Capital Inc. (operating as Elevate Financial), a company controlled by the Company's Chief Financial Officer, to provide bookkeeping, accounting and financial reporting services to the Company and its subsidiary. Fees under the arrangement are $5,500 per month for head office services and US$3,700 per month for the subsidiary. The arrangement has been in place since September 2022 and became a related party transaction on October 1, 2025, when the owner was appointed Chief Financial Officer of the Company. During the three months ended March 31, 2026, the Company incurred fees of $33,312 under this arrangement (March 31, 2025 — $nil, as the arrangement was not a related party transaction in that period).

10. SUPPLEMENTAL DISCLOSURES WITH RESPECT TO CASH FLOWS

	March 31, 2026	March 31, 2025
Cash received during the period for interest	$24,211	$31,188

Significant non-cash transactions as at and for the period ended March 31, 2026, are as follows:
a) Exploration and evaluation asset expenditures of $61,868 remain in accounts payable and accrued liabilities.

Significant non-cash transactions as at and for the period ended March 31, 2025, are as follows:
a) Exploration and evaluation asset expenditures of $181,499 remain in accounts payable and accrued liabilities.

11. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.

The significance of inputs used in making fair value measurements are examined and classified according to a fair value hierarchy. Fair values of assets and liabilities included in Level 1 are determined by reference to quoted market prices in active markets for identical assets and liabilities. Assets and liabilities in Level 2 include valuations using inputs other than quoted prices for which all significant outputs are observable, either directly or indirectly, and are based in valuation models and techniques where the inputs are derived from quoted indices. Level 3 valuations are based on inputs that are unobservable and significant to the overall fair value measurement.

Financial risk factors

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash and receivables. Management believes that the credit risk concentration with respect to financial instruments included in receivables is remote because these instruments are due primarily from government agencies. Further, the majority of the Company's cash and cash equivalents are held with the Bank of Montreal, a Canadian bank.

Liquidity risk

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when they come due. As at March 31, 2026, the Company had cash and cash equivalents of $10,504,389 (2025 - $5,200,725) to settle current liabilities of $213,914 (2025 - $184,900) and had working capital of $10,465,432 (2025 - $5,163,748). All of the Company's financial liabilities are subject to normal trade terms.

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates and foreign exchange rates. These fluctuations may be significant.

(a) Interest rate risk

The Company has cash balances and short-term investments held with financial institutions. The Company's current policy is to invest excess cash in savings accounts or guaranteed investment certificates issued by its banking institutions. The Company periodically monitors the investments it makes and is satisfied with the credit ratings of its banks. The Company has $10,119,761 in interest-bearing savings accounts with banks as at March 31, 2026 (December 31, 2025 - $4,915,773). A 1% change in interest rates would have an effect of $101,198 (2025 - $49,158) on interest income.

11. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Cont'd…)

(b) Foreign currency risk

The Company is exposed to foreign currency risk on fluctuations related to cash, receivables and accounts payable and accrued liabilities that are denominated in United States Dollars. The Company periodically monitors the investments it makes and is satisfied with the credit ratings of its banks. In addition to cash in US currency of $275,699 (December 31, 2025 - $218,242) as of March 31, 2026, the Company has $61,868 (December 31, 2025 - $125,203) in liabilities to US payees. A 1% change in foreign exchange rates would have an effect of $3,375 (2025 - $3,434) on foreign currency gain/loss.

12. SUBSEQUENT EVENTS

Grant of incentive stock options

On April 9, 2026, the Company granted an aggregate of 6,280,000 incentive stock options (the "Options") to directors, officers, employees and consultants of the Company. The Options are exercisable at $0.47 per share for a period of five years from the date of grant, expiring April 9, 2031. Of the Options granted, 1,700,000 Options granted to independent directors vested on the date of grant, and 4,580,000 Options granted to officers, employees and consultants vesting in equal tranches on the first, second, and third anniversaries of the date of grant.

The Options were granted under, and are governed by, the terms of the Company's LTIP and are subject to the policies of the TSX Venture Exchange.

Expiry of incentive stock options

On May 3, 2026, 750,000 incentive stock options held by a former officer of the Company expired unexercised. Upon expiry, the related fair value previously recognized in reserves remained within reserves, with no impact on profit or loss.